Prognostic and predictive biomarkers in mpm: a new era?

The new Bibliographic Review aims to offer an overview of the new era of biomarkers. There are biological markers capable of predicting the prognosis and response to therapy of a certain pathology, particularly neoplastic. This allows us to exploit valuable tools for predicting a patient's natural history.
In this context, malignant pleural mesothelioma (MPM) is also a neoplasm that could be studied by searching for prognostic and predictive biomarkers of response. However, there are no validated predictors of response to treatment or long-term outcomes, such as overall survival or progression-free survival. There are numerous studies that have examined ideal biomarkers as a predictive or prognostic approach to MPM: among these, substances present both in the pleural fluid and in the blood were analyzed to validate whether an analysis.
Regarding future perspectives, panels combining different markers and proteomic technologies are promising in terms of improving clinical performance in the diagnosis and monitoring of disease during specific treatment.
In this scenario we could see the beginning of a new era: obtaining important information on the disease and on the patient suffering from MPM, through inexpensive, repeatable and minimally invasive analyses: the discovery of ideal prognostic and predictive biomarkers.

Read more on the Bibliographic review page